Hycamtin (Topotecan)

Hycamtin is indicated for the systemic treatment of several malignant neoplasms where topoisomerase I inhibition is clinically beneficial.

• Ovarian cancer (as part of a chemotherapy regimen)
• Small cell lung cancer (in relapsed or refractory settings)
• Cervical cancer (for advanced disease)
• Other solid tumors as determined by the treating oncologist

• Topotecan, the active component of Hycamtin, binds to the DNA‑topoisomerase I complex and stabilizes it after it has introduced a single‑strand break. This prevents the re‑ligation step, leading to accumulation of DNA breaks during replication and transcription, ultimately triggering cell cycle arrest and apoptosis in rapidly dividing cancer cells.

Adverse reactions to Hycamtin can vary in frequency and severity.

Common

• Nausea and vomiting
• Diarrhea or constipation
• Fatigue or weakness
• Decreased white blood cell count (neutropenia)
• Anemia
• Decreased platelet count (thrombocytopenia)

Serious

• Severe neutropenia with fever (febrile neutropenia)
• Life‑threatening thrombocytopenia leading to bleeding
• Severe allergic or hypersensitivity reactions
• Secondary malignancies (rare)
• Severe, persistent diarrhea leading to dehydration

Before initiating Hycamtin therapy, several safety considerations should be addressed.

• Baseline and periodic monitoring of complete blood counts to detect myelosuppression
• Assessment of renal and hepatic function; dose adjustments may be required in impairment
• Contraindicated in pregnancy; effective contraception is advised for women of childbearing potential
• Evaluate for hypersensitivity to topotecan or any excipients
• Use caution in patients with active infections or immunosuppression
• Avoid concurrent use of other myelosuppressive agents unless clinically justified

Hycamtin may interact with other medicines, affecting efficacy or safety.

Avoid

• Strong enzyme inducers that may reduce topotecan exposure (e.g., rifampin)
• Other topoisomerase I inhibitors or agents with overlapping toxicity profiles
• Live vaccines during treatment due to immunosuppression risk

Use with caution

• Myelosuppressive chemotherapy agents (e.g., cyclophosphamide, carboplatin)
• Nephrotoxic drugs (e.g., cisplatin) that may exacerbate renal impairment
• Medications that prolong the QT interval
• Anticoagulants such as warfarin, as platelet reductions may increase bleeding risk
• Drugs that affect renal tubular secretion (e.g., probenecid)